VJHemOnc is committed to improving our service to you

EHA 2020 | DREAMM-2 & DREAMM-5: belantamab mafodotin for myeloma

VJHemOnc is committed to improving our service to you

Paul Richardson

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the DREAMM-2 and 5 trials (NCT04126200/NCT03525678) which are investigating belantamab mafodotin for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter